share_log

Emergent BioSolutions | 8-K: EMERGENT BIOSO LUTIONS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Emergent BioSolutions | 8-K: EMERGENT BIOSO LUTIONS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Emergent BioSolutions | 8-K：Emergent BIOSO LUTIONS 公佈2024年第二季度財務業績
美股SEC公告 ·  2024/08/07 04:27

Moomoo AI 已提取核心訊息

Emergent BioSolutions reported Q2 2024 total revenues of $254.7 million, down 25% YoY but above prior guidance. Net loss widened to $283.1 million from $261.4 million in Q2 2023. Adjusted EBITDA was -$10.1 million compared to $55.9 million last year.NARCAN Nasal Spray sales declined 10% to $120 million, while Anthrax MCM sales rose 83% to $38.7 million. The company secured over $250 million in U.S. government contract modifications for four medical countermeasures. It also resolved a contract dispute with Janssen Pharmaceuticals, receiving $50 million.Emergent updated its FY 2024 guidance, raising the midpoint for revenue to $1,050-$1,125 million and adjusted EBITDA to $140-$180 million. The company expects to exceed $200 million in debt reduction by year-end through asset sales and operational improvements. Management emphasized progress in stabilizing finances and sharpening focus on core products.
Emergent BioSolutions reported Q2 2024 total revenues of $254.7 million, down 25% YoY but above prior guidance. Net loss widened to $283.1 million from $261.4 million in Q2 2023. Adjusted EBITDA was -$10.1 million compared to $55.9 million last year.NARCAN Nasal Spray sales declined 10% to $120 million, while Anthrax MCM sales rose 83% to $38.7 million. The company secured over $250 million in U.S. government contract modifications for four medical countermeasures. It also resolved a contract dispute with Janssen Pharmaceuticals, receiving $50 million.Emergent updated its FY 2024 guidance, raising the midpoint for revenue to $1,050-$1,125 million and adjusted EBITDA to $140-$180 million. The company expects to exceed $200 million in debt reduction by year-end through asset sales and operational improvements. Management emphasized progress in stabilizing finances and sharpening focus on core products.
Emergent BioSolutions發佈了2024年第二季度總營業收入爲25470萬美元，同比下降25%，但超過了之前的指引。淨虧損從2023年第二季度的26140萬美元擴大至28310萬美元。調整後的息稅折舊攤銷前利潤（EBITDA）爲-1010萬美元，而去年爲5590萬美元。NARCAN噴霧劑銷量下降10%，降至12000萬美元，而炭疽MCm銷量上升83%，達到3870萬美元。該公司獲得了超過25000萬美元的美國政府合同修改，用於四種醫療對策。它還解決了與揚森製藥的合同糾紛，獲得5000萬美元的賠償。Emergent更新了2024財年的指引，將營業收入中位數上調至1050萬至112500萬美元，調整後的EBITDA上調至140萬至18000萬美元。該公司預計通過資產出售和運營改善，到年底將超過20000萬美元的債務減少。管理層強調在穩定財務和聚焦核心產品方面的進展。
Emergent BioSolutions發佈了2024年第二季度總營業收入爲25470萬美元，同比下降25%，但超過了之前的指引。淨虧損從2023年第二季度的26140萬美元擴大至28310萬美元。調整後的息稅折舊攤銷前利潤（EBITDA）爲-1010萬美元，而去年爲5590萬美元。NARCAN噴霧劑銷量下降10%，降至12000萬美元，而炭疽MCm銷量上升83%，達到3870萬美元。該公司獲得了超過25000萬美元的美國政府合同修改，用於四種醫療對策。它還解決了與揚森製藥的合同糾紛，獲得5000萬美元的賠償。Emergent更新了2024財年的指引，將營業收入中位數上調至1050萬至112500萬美元，調整後的EBITDA上調至140萬至18000萬美元。該公司預計通過資產出售和運營改善，到年底將超過20000萬美元的債務減少。管理層強調在穩定財務和聚焦核心產品方面的進展。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間